Mechanisms of OC related thrombosis

Thrombosis Research

Volumn 115, Issue SUPPL., 2005, Pages 81-83

  Rosing, J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; DESOGESTREL; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; GESTODENE; LEVONORGESTREL; LYNESTRENOL; NORETHISTERONE;

BLOOD CLOTTING; CARDIOVASCULAR RISK; CONFERENCE PAPER; CONTRACEPTION; DOWN REGULATION; FIBRIN CLOT; FIBRINOLYSIS; HEMOSTASIS; HUMAN; MUTATION; PATHOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM; THROMBOSIS;

BLOOD COAGULATION; CONTRACEPTIVES, ORAL, SEQUENTIAL; ESTRADIOL CONGENERS; FEMALE; HUMANS; PROGESTINS; THROMBOPHILIA; THROMBOSIS;

EID: 12544250961     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999;353:1167-73.
2. Jordan WM. Pulmonary embolism. Lancet 1961;2:1146-7.
3. WHO. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995;346:1582-8.
4. Olivieri O, Friso S, Manzato F, et al. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 1995;91:465-70.
5. Henkens CM, Bom VJ, Seinen AJ, et al. Sensitivity to activated protein C; influence of oral contraceptives and sex. Thromb Haemost 1995;73:402-4.
6. Dahlbáck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-8
7. Svensson PJ, Dahlbáck B. Resistance to activated protein C as a basis for venous thrombosis. New England Journal of Medicine 1994;330:517-22.
8. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
9. Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999;130:643-50.
10. de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999;93:1271-6.
11. Rosing J, Tans G, Nicolaes GA, et al. Oral contraceptives and venous thrombosis: Different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997;97:233-8.
12. Middeldorp S, Meijers JCM, van den Ende AE, et al. Effects on Coagulation of Levonorgestreland Desogestrel-containing Low Dose Oral Contraceptives: a Cross-over Study. Thromb Haemostas 2000;84:4-8.
13. Meijers JCM, Middeldorp S, Tekelenburg W, et al. Increased Fibrinolytic Activity during Use of Oral Contraceptives Is Counteracted by an Enhanced Factor XI-independent down Regulation of Fibrinolysis: A Randomized Cross-over Study of Two Low-dose Oral Contraceptives. Thromb Haemostas 2000;84:9-14.
14. Tans G, Curvers J, Middeldorp S, et al. A Randomized Cross-over Study on the Effects of Levonorgestrel- and Desogestrel-containing Oral Contraceptives on the Anticoagulant Pathways. Thromb Haemostas 2000;84:15-21.
15. Kemmeren JM, Algra A, Meijers JC, et al. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial. Blood 2004;103:927-33.